Abicipar is intended for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. Both diseases can cause blindness. The latest phase II trial, which was conducted on 151 patients, tested the drug for its efficacy in treating diabetic macular edema. cipar in allen Behandlungsgruppen nachgewiesen werden. Damit kann nun die Phase-III-Studie beginnen.
The results demonstrated Abicipar’s efficacy in all treatment groups, meaning the phase III trial can now begin. Molecular Partners explained that its partner Allergan was currently enrolling patients for the phase III trial, which will test Abicipar’s efficacy in the treatment of wet macular degeneration. The results of this trial are expected in 2018.
Molecular Partners was founded in 2004 as a spin-off from the University of Zurich (UZH) and is headquartered in the Bio-Technopark Schlieren-Zürich. The company developed the drug Abicipar, but it has a licensing agreement with the pharmaceutical company Allergan.